AntibioticDB

Oxantel

Fumarate reductase inhibitor

Oral Health CRC, Melbourne Dental School, Bio21 Institute, The University of Melbourne, Melbourne, Victoria, Australia

1975

Highest development stage: Preclinical
Development active
Gram-negative activity
Mechanism of Action/Target pathogen: Chronic periodontitis: proteolytic species Porphyromonas gingivalis and Tannerella forsythia
GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10840
Citation (1): http://aac.asm.org/content/58/1/378.full
Citation (2): https://www.ncbi.nlm.nih.gov/pubmed/12913453
Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/5281087